News Acquisitive Ipsen builds again with $952m Albireo buy French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.
Views & Analysis Q&A: Albireo’s Ron Cooper on bile acid modulation While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.
R&D Health Innovators – Jennifer Schranz In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.